Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share. This ...

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and cancer-related bone conditions.

Dr. Nicholas James discusses why it is important to identify which patients with high-risk prostate cancer will truly benefit from intensified treatment.

Human Rights Watch (HRW) released a report on Tuesday criticizing South Korea’s age-based employment laws and policies, finding that they systematically discriminated against older workers in ...

Live news, investigations, opinion, photos and video by the journalists of The New York Times from more than 150 countries around the world. Subscribe for coverage of U.S. and international news ...

The latest international news, investigations and analysis from Africa, the Americas, Asia, Australia, Canada, Europe, the Middle East and the U.K.